ArticleERJ open research2021
Severe outcomes of COVID-19 among patients with COPD and asthma.
Article in ERJ open research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Asthma and COVID-19 risk: a systematic review and meta-analysis.The European respiratory journal · 2022Pooled it
- Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations.Journal of clinical medicine · 2025Review
- Long-Term Effects of COVID-19 on Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Article
- Long-term effect of corticosteroid treatment during acute COVID-19 infection on pulmonary function test results.Journal of thoracic disease · 2024Article
- Association between asthma and COVID-19 severity during Omicron epidemic: a retrospective cohort study using real-world data.BMC infectious diseases · 2024Article
- Eosinophils and chronic obstructive pulmonary diseases (COPD) in hospitalized COVID-19 patients.BMC infectious diseases · 2024Article
- COPD patients with high blood eosinophil counts exhibit a lower rate of omicron infection and milder post-infection symptoms.The clinical respiratory journal · 2024Article
- The Complex Association between COPD and COVID-19.Journal of clinical medicine · 2023Review
- Features of Atrial Fibrillation Pathogenesis and Prognosis in Chronic Obstructive Pulmonary Patients during the COVID-19 Pandemic.Reviews in cardiovascular medicine · 2023Review
- Adult Severe Asthma Registries: A Global and Growing Inventory.Pragmatic and observational research · 2023Article
- Co-infection associated with SARS-CoV-2 and their management.Future science OA · 2022Review
- Sleep disorders and COVID-19.Sleep medicine · 2022Article
- Article
- Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study.Antibiotics (Basel, Switzerland) · 2021Article
- Asthma and COVID-19: a dangerous liaison?Asthma research and practice · 2021Review
- Living with the risk of being infected: COPD patients' experiences during the coronavirus pandemic.Journal of clinical nursing · 2021Article
- COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis.EClinicalMedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPatients with obstructive lung diseases are possibly at risk of developing severe outcomes of coronavirus disease 2019 (COVID-19). Therefore, the aim of this study was to determine the risk of severe outcomes of COVID-19 among patients with asthma and COPD.
methodsWe performed a nationwide cohort study of patients with COVID-19 from 1 February to 10 July 2020. All patients with COVID-19 registered in the Danish registers were included. Using International Classification of Diseases (ICD) codes and medication history, patients were divided into asthma, COPD or no asthma or COPD. Primary outcome was a combined outcome of severe COVID-19, intensive care or death.
resultsOut of 5104 patients with COVID-19 (median age 54.8 years (25-75th percentile 40.5 to 72.3); women, 53.0%), 354 had asthma and 432 COPD. The standardised absolute risk of the combined end-point was 21.2% (95% CI 18.8-23.6) in patients with COPD, 18.5% (95% CI 14.3-22.7) in patients with asthma and 17.2% (95% CI 16.1-18.3) in patients with no asthma or COPD. Patients with COPD had a slightly increased risk of the combined end-point compared with patients without asthma or COPD (risk difference 4.0%; 95% CI 1.3-6.6; p=0.003). In age standardised analyses, there were no differences between the disease groups. Low blood eosinophil counts (<0.3×10
conclusionPatients with COPD have a slightly increased risk of developing severe outcomes of COVID-19 compared with patients without obstructive lung diseases. However, in age-standardised analysis, the risk difference disappears.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.